Promising HS drug trial halted midway
Disease control
Terminated
This study tested a drug called izokibep for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. The drug aims to reduce inflammation by blocking a protein called IL-17A. The trial was terminated early, so results are not available. It included…
Phase: PHASE3 • Sponsor: ACELYRIN Inc. • Aim: Disease control
Last updated May 14, 2026 12:05 UTC